See more : Zhejiang Dahua Technology Co., Ltd. (002236.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Microbix Biosystems Inc. (MBXBF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Microbix Biosystems Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Volkswagen AG (VOW.DE) Income Statement Analysis – Financial Results
- Shuanghua Holdings Limited (1241.HK) Income Statement Analysis – Financial Results
- Bhartiya International Ltd. (BIL.NS) Income Statement Analysis – Financial Results
- PT Capital Financial Indonesia Tbk (CASA.JK) Income Statement Analysis – Financial Results
- Ellen AB (publ) (ELN.ST) Income Statement Analysis – Financial Results
Microbix Biosystems Inc. (MBXBF)
About Microbix Biosystems Inc.
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. It manufactures a range of critical biological materials for the diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment and proficiency (QAPs) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows. The company also applies its biological expertise and infrastructure to develop other proprietary products, primarily viral transport medium (DxTM) to stabilize patient samples for lab-based testing and Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots. It sells QAPs to lab accreditation organizations, diagnostics companies, and clinical labs through a network of regional distributors. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.51M | 19.08M | 18.59M | 10.52M | 13.41M | 12.51M | 10.19M | 9.52M | 8.87M | 8.40M | 7.57M | 6.67M | 6.23M | 6.46M | 6.08M | 4.99M | 4.05M | 3.64M | 4.38M | 4.07M | 2.85M | 2.81M | 2.99M | 1.86M | 1.60M | 3.10M | 2.70M |
| Cost of Revenue | 9.03M | 7.95M | 7.55M | 5.86M | 6.86M | 7.14M | 5.37M | 4.54M | 3.03M | 3.89M | 3.74M | 3.91M | 3.24M | 2.73M | 2.52M | 2.48M | 2.12M | 1.75M | 1.68M | 1.49M | 1.02M | 835.27K | 949.84K | 577.27K | 600.00K | 600.00K | 500.00K |
| Gross Profit | 7.48M | 11.12M | 11.04M | 4.66M | 6.55M | 5.37M | 4.81M | 4.98M | 5.84M | 4.51M | 3.83M | 2.75M | 2.98M | 3.73M | 3.56M | 2.51M | 1.93M | 1.89M | 2.70M | 2.58M | 1.82M | 1.97M | 2.04M | 1.28M | 1.00M | 2.50M | 2.20M |
| Gross Profit Ratio | 45.30% | 58.32% | 59.40% | 44.28% | 48.82% | 42.92% | 47.25% | 52.33% | 65.81% | 53.73% | 50.62% | 41.30% | 47.92% | 57.78% | 58.60% | 50.36% | 47.74% | 51.94% | 61.72% | 63.36% | 64.03% | 70.24% | 68.22% | 68.91% | 62.50% | 80.65% | 81.48% |
| Research & Development | 2.05M | 1.80M | 1.03M | 1.01M | 1.04M | 1.09M | 994.58K | 493.61K | 1.28M | 691.07K | 445.82K | 560.00K | 530.07K | 494.25K | 703.06K | 1.19M | 985.42K | 886.05K | 572.87K | 966.80K | 668.39K | 443.78K | 346.67K | 228.62K | 3.80M | 1.60M | 900.00K |
| General & Administrative | 6.53M | 5.00M | 4.22M | 3.54M | 3.74M | 3.61M | 3.93M | 3.13M | 2.87M | 1.85M | 1.79M | 2.25M | 2.24M | 2.96M | 2.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 1.48M | 1.55M | 858.06K | 632.55K | 651.46K | 556.41K | 464.91K | 517.02K | 602.23K | 656.99K | 893.58K | 1.52M | 1.39M | 1.47M | 1.46M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.01M | 6.56M | 5.07M | 4.17M | 4.40M | 4.17M | 4.39M | 3.65M | 3.47M | 2.50M | 2.68M | 3.77M | 3.64M | 4.43M | 4.35M | 4.46M | 3.02M | 2.68M | 1.81M | 1.51M | 1.43M | 1.26M | 1.20M | 1.24M | 1.50M | 2.60M | 1.20M |
| Other Expenses | 161.24K | 160.34K | 99.40K | 0.00 | 0.00 | 0.00 | -273.54K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 10.22M | 8.51M | 6.21M | 5.19M | 5.44M | 5.26M | 5.39M | 4.14M | 4.75M | 3.19M | 3.09M | 4.33M | 4.63M | 5.39M | 5.93M | 6.00M | 4.27M | 3.81M | 2.55M | 2.63M | 2.25M | 1.86M | 1.73M | 1.67M | 5.60M | 4.50M | 2.30M |
| Cost & Expenses | 19.25M | 16.47M | 13.76M | 11.05M | 12.30M | 12.40M | 10.76M | 8.68M | 7.78M | 7.08M | 6.83M | 8.25M | 7.87M | 8.11M | 8.45M | 8.48M | 6.39M | 5.56M | 4.23M | 4.12M | 3.27M | 2.70M | 2.68M | 2.25M | 6.20M | 5.10M | 2.80M |
| Interest Income | 457.74K | 82.27K | 66.00 | 1.06M | 1.07M | 172.00 | 22.00 | 616.00 | 2.79K | 9.81K | 9.16K | 159.00 | 3.50K | 2.00K | 46.14K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 839.38K | 826.56K | 1.60M | 1.06M | 1.07M | 852.03K | 924.61K | 691.25K | 745.22K | 850.88K | 718.78K | 1.06M | 976.03K | 889.68K | 161.59K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.16M | 1.04M | 822.04K | 690.09K | 568.82K | 690.08K | 510.16K | 413.68K | 418.42K | 403.26K | 419.20K | 431.23K | 460.76K | 457.09K | 410.49K | 355.71K | 273.39K | 242.64K | 166.59K | 154.08K | 153.92K | 160.52K | 180.25K | 207.36K | 300.00K | 300.00K | 200.00K |
| EBITDA | 1.96M | 3.33M | 5.39M | -95.44K | 1.54M | -7.08M | -2.80M | 1.25M | 1.51M | 1.73M | 1.31M | -1.25M | -1.08M | -1.19M | -1.31M | -3.13M | -2.07M | -1.68M | 317.60K | 101.14K | -272.42K | 266.86K | 493.44K | -186.30K | -4.40M | -1.90M | 100.00K |
| EBITDA Ratio | 11.85% | 19.55% | 30.43% | 1.57% | 12.52% | 6.39% | -3.32% | 13.17% | 17.05% | 20.60% | 15.51% | -17.17% | -18.90% | -18.47% | -21.60% | -62.77% | -51.07% | -45.97% | 7.26% | 2.49% | -9.57% | 9.51% | 16.51% | -10.03% | -268.75% | -54.84% | 3.70% |
| Operating Income | -2.74M | 2.69M | 4.84M | -524.60K | 1.11M | -742.81K | -1.50M | 148.41K | 348.98K | 475.62K | 168.18K | -1.58M | -1.64M | -1.65M | -1.72M | -3.49M | -2.34M | -1.92M | 151.02K | -52.95K | -426.33K | 106.34K | 313.18K | -393.66K | -4.60M | -2.00M | -100.00K |
| Operating Income Ratio | -16.57% | 14.11% | 26.01% | -4.98% | 8.27% | -5.94% | -14.72% | 1.56% | 3.93% | 5.66% | 2.22% | -23.63% | -26.35% | -25.54% | -28.35% | -69.89% | -57.83% | -52.63% | 3.45% | -1.30% | -14.98% | 3.79% | 10.48% | -21.20% | -287.50% | -64.52% | -3.70% |
| Total Other Income/Expenses | 2.70M | -744.29K | -1.60M | -4.13M | -1.07M | -7.88M | -2.73M | -689.61K | -742.44K | -752.12K | 311.81K | -812.73K | -1.02M | -887.68K | 0.00 | 0.00 | -370.57K | -174.11K | 62.51K | 153.76K | 112.50K | 18.57K | 31.16K | 20.08K | 0.00 | 100.00K | 100.00K |
| Income Before Tax | -39.48K | 1.87M | 3.23M | -4.66M | 43.68K | -8.62M | -4.23M | 148.41K | 348.98K | 475.62K | 168.18K | -2.64M | -2.61M | -2.54M | 0.00 | 0.00 | -2.71M | -2.09M | 213.53K | 97.06K | -313.83K | 124.91K | 344.35K | -373.58K | 0.00 | -1.90M | 0.00 |
| Income Before Tax Ratio | -0.24% | 9.78% | 17.39% | -44.27% | 0.33% | -68.91% | -41.53% | 1.56% | 3.93% | 5.66% | 2.22% | -39.53% | -41.97% | -39.28% | 0.00% | 0.00% | -66.98% | -57.41% | 4.88% | 2.39% | -11.02% | 4.45% | 11.52% | -20.12% | 0.00% | -61.29% | 0.00% |
| Income Tax Expense | 0.00 | 77.23K | 1.60M | 1.57M | 11.76K | 852.03K | -450.00K | -600.00K | -265.00K | 306.65K | 166.80K | 159.00 | 3.50K | 887.68K | 759.98K | 177.83K | 0.00 | 211.61K | 88.00K | 82.79K | 49.88K | 55.40K | 103.23K | 76.65K | 100.00K | 200.00K | 100.00K |
| Net Income | -39.48K | 1.79M | 1.63M | -6.23M | 31.92K | -8.62M | -3.78M | 748.41K | 613.98K | 168.98K | 1.38K | -2.64M | -2.61M | -2.54M | -2.48M | -3.67M | -2.71M | -2.09M | 125.53K | 14.27K | -363.71K | 69.51K | 241.12K | -450.23K | -4.70M | -2.10M | -100.00K |
| Net Income Ratio | -0.24% | 9.38% | 8.77% | -59.17% | 0.24% | -68.91% | -37.11% | 7.86% | 6.92% | 2.01% | 0.02% | -39.53% | -41.97% | -39.28% | -40.85% | -73.45% | -66.98% | -57.41% | 2.87% | 0.35% | -12.78% | 2.48% | 8.07% | -24.25% | -293.75% | -67.74% | -3.70% |
| EPS | 0.00 | 0.01 | 0.01 | -0.06 | 0.00 | -0.09 | -0.04 | 0.01 | 0.01 | 0.00 | 0.00 | -0.04 | -0.05 | -0.05 | -0.05 | -0.08 | -0.07 | -0.06 | 0.00 | 0.00 | -0.01 | 0.00 | 0.01 | -0.01 | -0.14 | -0.06 | 0.00 |
| EPS Diluted | 0.00 | 0.01 | 0.01 | -0.06 | 0.00 | -0.09 | -0.04 | 0.01 | 0.01 | 0.00 | 0.00 | -0.04 | -0.05 | -0.05 | -0.05 | -0.08 | -0.07 | -0.06 | 0.00 | 0.00 | -0.01 | 0.00 | 0.01 | -0.01 | -0.14 | -0.06 | 0.00 |
| Weighted Avg Shares Out | 138.05M | 135.38M | 114.85M | 104.84M | 96.97M | 95.80M | 84.70M | 84.66M | 80.87M | 68.98M | 66.60M | 61.93M | 54.84M | 48.63M | 46.45M | 45.85M | 38.74M | 34.87M | 34.91M | 34.50M | 36.37M | 34.48M | 34.48M | 34.37M | 33.57M | 35.00M | 32.32M |
| Weighted Avg Shares Out (Dil) | 137.91M | 141.69M | 141.68M | 104.84M | 97.09M | 96.20M | 84.70M | 84.71M | 82.15M | 72.23M | 66.60M | 61.93M | 54.84M | 48.63M | 46.45M | 45.85M | 38.74M | 34.87M | 34.91M | 34.50M | 36.37M | 34.48M | 34.48M | 34.37M | 33.57M | 35.00M | 32.32M |
Microbix Announces Initiation of Normal Course Issuer Bid
MISSISSAUGA, Ontario, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®) (“Microbix” or the “Company”), a life sciences innovator, manufacturer, and exporter, announces the initiation of a Normal Course Issuer Bid (“NCIB”) program for the...
Microbix Presents Novel HSV Test Control at EMMD
MISSISSAUGA, Ontario, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, announces that it is presenting results of a novel Quality Assessment Product (“QAP™”) for supporting patient...
Microbix Achieves Essential EU Regulatory Accreditations
MISSISSAUGA, Ontario, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it has upgraded its European Union (“EU”) regulatory compliance for its diagnostic assay quality assessment...
Microbix Presenting at Muskoka Capital Conference
MISSISSAUGA, Ontario, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, announces that it will be presenting to investors at the Muskoka Capital Conference, organized by Capital...
Microbix Reports Continued Strong Results for Q3 Fiscal 2024
MISSISSAUGA, Ontario, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, reports results for its third quarter and first nine months of fiscal 2024 ended June 30,...
Microbix Schedules Release of Results for Q3 Fiscal 2024
MISSISSAUGA, Ontario, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements and management disclosure and analysis for its...
Microbix Presents HCV FLOQSwab® Format Test Control at ADLM
MISSISSAUGA, Canada, July 25, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, announces that it is presenting results of a novel Quality Assessment Product (“QAP™”) for supporting Point-of-Care-Tests...
Microbix Hosts Minister Nina Tangri to Open Capacity Expansions
Adds Product Development & QC Labs, Fully-Automated IVD Vial-Filling Capability Adds Product Development & QC Labs, Fully-Automated IVD Vial-Filling Capability
Microbix Advances Test-Ingredient Manufacturing Capabilities
Bioreactor Production of a Second Major Antigen – Increasing Capacity and Flexibility Bioreactor Production of a Second Major Antigen – Increasing Capacity and Flexibility
Microbix Biosystems Inc. (MBXBF) Q2 2024 Earnings Call Transcript
Microbix Biosystems Inc. (OTCQX:MBXBF) Q2 2024 Earnings Conference Call May 15, 2024 10:00 AM ET Company Participants Deborah Honig - Investor Relations Cameron Groome - Chief Executive Officer Jim Currie - Chief Financial Officer Ken Hughes - Chief Operating Officer...
Source: https://incomestatements.info
Category: Stock Reports